Sign in Subscribe
Clinical trials

Breakthrough in Conjugate Vaccine Research: Enhancing Pneumococcal Disease Protection in Children

Strategic Insights

— 1 min read

Researchers from Pfizer have made a significant discovery in the field of conjugate vaccines, developing a 20-valent pneumococcal conjugate vaccine (PCV20) to extend protection against pneumococcal disease. The phase 3 study, which has been peer-reviewed, assessed the safety and immunogenicity of PCV20 in children aged 15 months to 3 years, who had previously received 3 doses of a 13-valent PCV (PCV13). The study found that PCV20 was well-tolerated, with mostly mild to moderate local reactions and systemic events. Notably, the vaccine elicited robust serotype-specific IgG concentrations and opsonophagocytic activity (OPA) titers in children aged 5 years and above.

Key Takeaways:

  • The 20-valent pneumococcal conjugate vaccine (PCV20) was developed to extend protection against pneumococcal disease in children.
  • The phase 3 study assessed the safety and immunogenicity of PCV20 in children aged 15 months to 3 years who had previously received 3 doses of PCV13.
  • Of 839 enrolled participants, 831 (99%) were vaccinated, and 819 (97%) completed all study visits.
  • Local reactions and systemic events were mostly mild to moderate in severity.
  • The vaccine elicited robust serotype-specific IgG concentrations and opsonophagocytic activity (OPA) titers in children aged 5 years and above.
  • IgG geometric mean fold rises (GMFRs) from before to 1 month after PCV20 ranged from 27.9-1847.7 (7 additional serotypes) and 2.9-44.9 (PCV13 serotypes) in children ages 5 years old.
  • OPA GMFRs from before to 1 month after PCV20 ranged from 12.4-983.6 to 2.8-52.9 in children ages 5 years of age.

Statistics:

  • 839 participants were enrolled in the study.
  • 831 (99%) participants were vaccinated.
  • 819 (97%) participants completed all study visits.
  • IgG GMFRs ranged from 27.9-1847.7 in 7 additional serotypes and 2.9-44.9 in PCV13 serotypes.
  • OPA GMFRs ranged from 12.4-983.6 in 7 additional serotypes and 2.8-52.9 in PCV13 serotypes.

Sources:

  • NewsRx. Studies from Pfizer Reveal New Findings on Conjugate Vaccines (A Phase 3, Single-arm Trial To Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine In Healthy Children 15 Months Through
  • A Phase 3, Single-arm Trial To Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine In Healthy Children 15 Months Through

Read more